Trial Profile
Phase I Study of Intramuscular (IM) Injections of Allogeneic PLX-PAD Cells for the Treatment of Critical Limb Ischemia. PLX-PAD Are Mesenchymal-Like Stromal Cells Derived From a Full Term Placenta.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 04 Apr 2023
Price :
$35
*
At a glance
- Drugs Emiplacel (Primary)
- Indications Chronic limb-threatening ischemia
- Focus Adverse reactions
- Sponsors Pluristem Therapeutics
- 13 Mar 2023 ording to a Pluristem Therapeutics media release, Pluristem Therapeutics has changed its name to Pluri Inc.
- 18 May 2015 According to a Pluristem Therapeutics media release, the PLX cell program in critical limb ischemia has been selected for the European Medicines Agency's Adaptive Pathways pilot project.
- 27 Nov 2014 New trial record